Clinical trials: insulin glargine
Type 2 Diabetes
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA
The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
- Trial name
- NCT00732524
- Testing
- Glipizide, Glipizide and Glargine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cook County Health
Diabetic Ketoacidosis
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.
- Trial name
- NCT00179127
- Testing
- glargine, saline
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes
- Trial name
- NCT00553020
- Testing
- Insulin glargine
- Volunteers
- 16 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes Mellitus
Effects of Metformin in Heart Failure Patients
Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety.
- Trial name
- NCT02694289
- Testing
- Metformin, Subcutaneous (sliding scale) Insulin
- Sponsor
- Maya Guglin
Hyperglycemia
Sitagliptin in Non-Diabetic Patients Undergoing General Surgery
The purpose of this study is to compare sitagliptin with a placebo for the prevention of high glucose after general surgery.
- Trial name
- NCT02741687
- Testing
- Sitagliptin, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart)
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Emory University
Type 2 Diabetes
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to…
- Trial name
- NCT02455076
- Testing
- Exenatide, Glargine, Rapid-acting insulin analogs
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
Acute Stroke, Hyperglycemia
Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke
Hyperglycemia is common during acute ischemic stroke. However, the optimal strategy to control hyperglycemia during acute ischemic stroke has not been established.
- Trial name
- ICAS (NCT02607943)
- Testing
- Insulin Glargine, Regular Insulin
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Diabetes Mellitus, Type 2
Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors
To compare the impact of insulin degludec (IDeg-100) and insulin glargine U300 (IGlar-300) on cardiovascular risk parameters - glycaemic variability (GV), oxidative stress, arterial stiffness and lipid parameters - in insulin…
- Trial name
- NCT04692415
- Testing
- Degludec, Glargine U300
- Where
- Croatia
- Volunteers
- 25 people
- Sponsor
- University of Split, School of Medicine
Diabetes Mellitus, Type 2
Effects of Insulin Glargine and Lixisenatide on the Brain
1. Background During the last years, the brain has been identified as a major insulin-sensitive organ . The investigators and also other scientists identified hypothalamus, fusiform gyrus and prefrontal cortex as major…
- Trial name
- Lixibrain01 (NCT03881995)
- Testing
- IGlarLixi, Insulin Glargine 100 UNT/ML
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital Tuebingen
Diabetes Type 1
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
A randomized, crossover, open study in order to compare treatment satisfaction with insulin Glargine plus insulin Apidra Vs NPH insulin plus insulin Apidra in newly diagnosed children and adolescents with type 1 diabetes.
- Trial name
- NCT00925977
- Testing
- insulin Glargine + Insulin Apidra, Insulin NPH + Insulin Apidra: Active Comparator
- Where
- 4 sites in Israel
- Volunteers
- 44 people
- Sponsor
- Rabin Medical Center
Type 2 Diabetes
SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
In noncritically hospitalized patients, hyperglycemia (defined as blood glucose [BG] levels >140 mg/dL) is a common, serious, and costly healthcare problem.
- Trial name
- SITAGLAR-H (NCT05579119)
- Testing
- Sitagliptin 100mg, Glargine, Lispro
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both…
- Trial name
- BOOST™ (NCT01045707)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 92 sites in United States, Austria and 7 more
- Volunteers
- 530 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: Change in participants' overall blood sugar control The rate of night time low…
- Trial name
- IMAGINE 5 (NCT01582451)
- Testing
- LY2605541, Insulin glargine
- Where
- 61 sites in United States, Czechia and 7 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with…
- Trial name
- NCT01569841
- Testing
- insulin degludec, insulin glargine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Secondary Drug Failure
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
- Trial name
- NCT00609856
- Testing
- pioglitazone, insulin glargine
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Skane University Hospital
Type2 Diabetes Mellitus
Empagliflozin Effect on Glucose Toxicity
Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study
- Trial name
- NCT03437330
- Testing
- Empagliflozin (Jardiance®), Insulin Glargine (Lantus®)
- Where
- 2 sites in Germany
- Sponsor
- University Hospital Tuebingen
Type 2 Diabetes
GLP-1 REceptor Agonists and Real World EvIdeNce
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are powerful second-line agents for the treatment of type 2 diabetes. GLP-1RA have bene marketed in 2010 in Italy and years of experience have accumulated for the treatment with…
- Trial name
- GLP-1REWIN (NCT03959865)
- Testing
- Long-acting GLP-1RA, Short-acting GLP-1RA, Human-based GLP-1RA
- Where
- 6 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- University of Padova